Pfizer and Rosa to present at 2012 Keystone Symposia: Pathogenesis of Diabetes
Insulin degradation and the mechanisms controlling it have significant impact on glucose homeostasis and diabetes.

SAN CARLOS, CA, January 26, 2012 /24-7PressRelease/ -- Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that the results from a recent collaborative research project with Pfizer will be presented at the 2012 Keystone Symposia: "Pathogenesis of Diabetes: Emerging Insights into Molecular Mechanisms" in Santa Fe, New Mexico on Monday, January 30, 2012. Dr. Rebecca Baillie will be presenting a poster entitled "Novel insights into the importance of insulin degradation in glucose metabolism". The poster will describe the critical contribution of insulin degradation to patient variability in insulin and glucose homeostasis. This work will also highlight the use of a Diabetes PhysioPD model to gain additional insight from clinical data and to evaluate and test multiple hypotheses regarding insulin degradation.

"We are pleased to present results from this collaboration with Pfizer. This work is a demonstration of how modeling can be used to advance fundamental scientific understanding relevant to drug development, extract more value from clinical data, and systematically evaluate alternate biological hypotheses," said Dr. Mike Reed, Rosa's Vice President of Client Services.

Press Release Contact Information:

Rebecca Baillie
Rosa & Co
Chief Scientist
751 Laurel St., Ste. 127,
San Carlos, CA
USA 94070
Voice: 530-661-7476
Website: Visit Our Website